{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"127","value":"400"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"606"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Atezolizumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic (PK) evaluable population included participants who received atezolizumab treatment and had at least one measurable PK concentration.","reportingStatus":"POSTED","timeFrame":"Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days)","title":"Maximum Observed Serum Atezolizumab Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"Microgram per milliliter (mcg/mL)"}